WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDAapproved RhodoLED XL, a red light emitting LED lamp. This innovative device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuver and able to accommodate ...

Forward-Looking Statements WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDAapproved RhodoLED XL, a red light emitting LED lamp. This innovative device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuv ...

Biofrontera Inc. (NASDAQ:BFRI) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in list ...

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update. ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily dr ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC For the quarterly period ended March 31, 2024 For the transition period from to Delaware 47-3765675 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Not Applicable (Former name, form ...

Biofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Conference Call March 18, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman & Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Incorporated Fourth Quarter 2023 Financial Results and Business Update Conference Call. All participants will be in listen-on ...

Our principal licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLEDlamp series, for PDT (when used together, "Ameluz PDT"). In the United States, the PDT treatment is used for the lesion-directed and fielddirected treatment of actinic keratoses ("AK") of mild-to-moderate severity on the face and scalp. AKs are premalignant lesions of the skin that can potentially develop into skin cancer (squamous cell carcinoma) if left untreated.International treatment ...

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Conference Call November 10, 2023 10:00 AM ET Company Participants Tirth Patel - IR Hermann Luebbert - Chairman, CEO and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the c ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2023 Commission file number 001-40943 | --- | --- | --- | |------------------------------------------------------|---------------------|-------------------------------------------------------| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common stock, par value $0.001 per share | BFRI | The Nasdaq Stock Market LLC | | Preferred Stock Pur ...

Biofrontera Inc. (NASDAQ:BFRI) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good morning everyone and welcome to the Biofrontera Inc. Second Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please also note ...